EX-99.1 2 ex991.htm MATERIAL CHANGE REPORT - CARDIOME AND ASTELLAS ANNOUNCE POSITIVE RESULTS FROM ACT 2 TRIAL MATERIAL CHANGE REPORT - CARDIOME AND ASTELLAS ANNOUNCE POSITIVE RESULTS FROM ACT 2 TRIAL
 
Exhibit 99.1
FORM 53-901F
 
SECURITIES ACT
 
MATERIAL CHANGE REPORT UNDER
SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)
AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS
 
Item 1.
REPORTING ISSUER
 
Cardiome Pharma Corp.
6190 Agronomy Road, 6th Floor
Vancouver, BC V6T 1Z3
 
Item 2.
DATE OF MATERIAL CHANGE
 
June 4, 2007
 
Item 3.
PRESS RELEASE
 
June 4, 2007 - Vancouver, Canada and Deerfield, Illinois, USA
 
Item 4.
SUMMARY OF MATERIAL CHANGE
 
Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today announced results from their recently completed Phase 3 clinical study, called ACT 2. The trial evaluated the efficacy and safety of the intravenous formulation of vernakalant hydrochloride (“vernakalant (iv)”) for the treatment of patients who developed atrial fibrillation or atrial flutter between 24 hours and 7 days following coronary artery bypass graft (CABG) or valve replacement surgery. In the atrial fibrillation population, 47% of patients dosed with vernakalant (iv) experienced conversion to normal heart rhythm within 90 minutes, as compared to 14% of placebo patients, a statistically significant difference (p=0.0001).

Item 5.
FULL DESCRIPTION OF MATERIAL CHANGE

See attached press release

Item 6.
RELIANCE ON SECTION 85(2) OF THE SECURITIES ACT (BRITISH COLUMBIA) AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS
 
Not Applicable.
 
Item 7.
OMITTED INFORMATION
 
Not Applicable.
 
Item 8.
SENIOR OFFICER
 
Name: Curtis Sikorsky
Title: Chief Financial Officer
Phone No.: 604-677-6905
 
Item 9.
STATEMENT OF SENIOR OFFICER
 
The foregoing accurately discloses the material change referred to herein.
 
 
 
 
Dated at Vancouver, British Columbia, this 4th day of June, 2007.
 
     
  CARDIOME PHARMA CORP.
 
 		  
 		  
 
  Per:      “Curtis Sikorsky”
 
Curtis Sikorsky,
  Chief Financial Officer
 
IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.